Filing Details

Accession Number:
0001181431-12-042070
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-07-25 15:31:12
Reporting Period:
2012-07-24
Filing Date:
2012-07-25
Accepted Time:
2012-07-25 15:31:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1544116 Durata Therapeutics Inc. DRTX Pharmaceutical Preparations (2834) 871247903
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1202793 Michael Powell C/O Sofinnova Ventures
2800 Sand Hill Road, Suite 150
Menlo Park CA 94025
No No Yes No
1245624 James Healy C/O Sofinnova Ventures
2800 Sand Hill Road, Suite 150
Menlo Park CA 94025
Yes No Yes No
1362314 Eric Buatois C/O Sofinnova Ventures
2800 Sand Hill Road, Suite 150
Menlo Park CA 94025
No No Yes No
1380734 P L Vii Partners Venture Sofinnova C/O Sofinnova Ventures
2800 Sand Hill Road, Suite 150
Menlo Park CA 94025
No No Yes No
1421501 Sofinnova Management Vii, L.l.c. C/O Sofinnova Ventures
2800 Sand Hill Road, Suite 150
Menlo Park CA 94025
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-07-24 1,683,094 $0.00 1,683,094 No 4 C Indirect See footnote
Common Stock Acquisiton 2012-07-24 588,236 $9.00 2,271,330 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 P Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2012-07-24 1,683,094 $0.00 1,683,094 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 6,250 Direct
Footnotes
  1. All outstanding shares of the Issuer's Series A Preferred Stock, including the 13,464,758 shares held by the Reporting Persons, were automatically converted into Common Stock on a 1-for-0.125 basis upon the closing of the Issuer's initial public offering for no additional consideration.
  2. Shares are owned directly by Sofinnova Venture Partners VII, L.P. ("SV VII"). Sofinnova Management VII, L.L.C. ("SV VII LLC"), the general partner of SV VII, and James Healy, a director of the Issuer, Michael Powell, and Eric Buatois, the managing members of SV VII LLC, may be deemed to have shared voting and dispositive power over the shares owned by SV VII . Such persons and entities disclaim beneficial ownership over the shares owned by SV VII except to the extent of any pecuniary interest therein.
  3. The shares were purchased in the Issuer's initial public offering.
  4. The shares are owned directly by Mr. Healy.